Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]
In development
Reference number: GID-TA11768
Expected publication date:
To appraise the clinical and cost effectiveness of Rituximab + Lenalidomide + Epcoritamab within its marketing authorisation for treating follicular lymphoma